About the Company
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CODX News
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 14, 2024 Co-Diagnostics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the ...
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
SALT LAKE CITY, Utah, March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a ...
Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost
Yi Chen, an analyst from H.C. Wainwright, reiterated the Hold rating on Co-Diagnostics (CODX – Research Report). The associated price ...
Co-Diagnostics Inc Registered Shs
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Earnings Preview: Co-Diagnostics
Analysts estimate that Co-Diagnostics will report an earnings per share (EPS) of $-0.20. Co-Diagnostics bulls will hope to ...
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test
CVS Health, Inc. CVS company — Signify Health — recently launched a new heart arrhythmia test. The addition of new test expands the company’s Diagnostic and Preventive Services offering. It is worth ...
The global food diagnostics services market is expected to reach US$21.6 billion by 2032, driven by growing concerns about food
The Global Food Diagnostics Services Market By the end of 2032, it is projected to have grown from an estimated value of US$ ...
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “ human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
ThreeD Capital Inc. Announces Private Placement with Sariel Diagnostics Corp.
ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive ...
Loading the latest forecasts...